Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Medical composition of levamlodipine or pharmaceutically acceptable salt thereof and beta-blocker and application thereof

A technology of levamlodipine and levammonium chloride, which is applied in the direction of drug combinations, pharmaceutical formulas, medical preparations containing active ingredients, etc., can solve the problem of limited contribution of drug dosage, reduce the incidence rate, improve the quality of life, The effect of reducing adverse reactions

Active Publication Date: 2010-07-07
SHIHUIDA PHARMA GRP (JILIN) LTD
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are reports on the combined use of hypertension drugs, because this can reduce the dose of a single drug and reduce adverse reactions, and the combined use of some drugs can offset each other’s adverse reactions, but many drugs may not be able to lower blood pressure when combined. Synergy, in this case, limited contribution to dose reduction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical composition of levamlodipine or pharmaceutically acceptable salt thereof and beta-blocker and application thereof
  • Medical composition of levamlodipine or pharmaceutically acceptable salt thereof and beta-blocker and application thereof
  • Medical composition of levamlodipine or pharmaceutically acceptable salt thereof and beta-blocker and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0024] The preparation of embodiment 1-10 compound tablet

[0025]

[0026]

[0027]

[0028] Preparation process: put levamlodipine, β receptor blocker, microcrystalline cellulose, pregelatinized starch, lactose, and hydroxymethyl starch sodium into a mortar, grind and mix evenly, pass through a 20-mesh sieve, and add an appropriate amount of 95% Ethanol is made into a soft material, granulated through a 20-mesh sieve, ventilated and dried at 40°C, the dry granules are sized with a 16-mesh sieve, magnesium stearate is added, mixed evenly, and then compressed into tablets.

[0029] Dosage: Take orally, once a day, 1-2 tablets each time, in the morning.

[0030] The preparation of embodiment 11-15 compound capsule

[0031]

[0032]

[0033] Preparation process: put levamlodipine, β-receptor blocker, and microcrystalline cellulose into a mortar, grind and mix evenly, pass through a 20-mesh sieve, add an appropriate amount of 0.5% PVP-k30 ethanol solution to make ...

example 16

[0036] The antihypertensive test of example 16 rats

[0037] Experimental method: Take 120 healthy spontaneously hypertensive SHR rats, half male and half female, weighing 200-240g, male and female rats are divided into 12 groups according to the balance of blood pressure (see Table 1 for the specific grouping method), and the drug is administered by intragastric administration For blood pressure, rat electronic sphygmomanometers were used to indirectly measure the systolic blood pressure of the rats when they were awake and quiet by the tail volume method.

[0038] Table 1: Grouping methods

[0039]

[0040]

[0041] Experimental results: single drug 1 group, single drug 2 groups, single drug 3 groups, single drug 4 groups, single drug 5 groups, single drug 6 groups, compound 1 group, compound 2 groups, compound 3 groups, compound 4 groups, compound Compared with the model group, group 5, group 6, group 7, group 8, group 9, and group 10 had a significant antihypertensive...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a medical composition of levamlodipine or a pharmaceutically acceptable salt thereof and a beta-blocker and an application thereof. The active ingredients of the medical composition contain levamlodipine or a pharmaceutically acceptable salt thereof and a beta-blocker. The beta-blocker is selected from one of nebivolol, bisoprolol, betaxolol, celiprolol and nadolol. The present invention also discloses an application of the medical composition to the preparation of a medicament for treating hypertension. The medical composition has the characteristics of evident therapeutic effect and convenient administration.

Description

technical field [0001] The present invention relates to a drug for treating hypertension, in particular to a composition comprising levamlodipine or a pharmaceutically acceptable salt thereof and a beta receptor blocker and application thereof. Background technique [0002] In recent years, with the continuous improvement of people's living standards in our country and the change of dietary structure, the increase of life pressure, and the increase of the elderly population, the incidence of hypertension has gradually increased, and it will cause heart, brain, kidney, etc. It is closely related to the disorder of sugar and lipid metabolism and diabetes, which obviously reduces the quality of life of the patient, and even endangers the life of the patient in severe cases. According to the World Health Organization (WHO) statistics on the death of various diseases in the world, the death toll of cardiovascular and cerebrovascular diseases represented by hypertension accounts f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4422A61K31/353A61K31/138A61K31/17A61P9/12A61P9/04A61P9/00
CPCA61K31/138A61K31/17A61K31/353A61K45/06A61K31/4422A61P9/00A61P9/04A61P9/10A61P9/12A61P43/00A61K2300/00
Inventor 杨彦玲薛传校张喜田李环宋森涛
Owner SHIHUIDA PHARMA GRP (JILIN) LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com